Skip to main navigation Skip to search Skip to main content

CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations

  • M. A. Province
  • , M. P. Goetz
  • , H. Brauch
  • , D. A. Flockhart
  • , J. M. Hebert
  • , R. Whaley
  • , V. J. Suman
  • , W. Schroth
  • , S. Winter
  • , H. Zembutsu
  • , T. Mushiroda
  • , W. G. Newman
  • , M-T M. Lee
  • , C. B. Ambrosone
  • , M. W. Beckmann
  • , J-Y Choi
  • , A-S Dieudonné
  • , P. A. Fasching
  • , R. Ferraldeschi
  • , L. Gong
  • E. Haschke-Becher, A Howell, L. B. Jordan, U. Hamann, K. Kiyotani, P. Krippl, D. Lambrechts, A Latif, U. Langsenlehner, W. Lorizio, P. Neven, A. T. Nguyen, B-W Park, C. A. Purdie, P. Quinlan, W. Renner, M. Schmidt, M. Schwab, J-G Shin, J. C. Stingl, P. Wegman, S. Wingren, A. H. B. Wu, E. Ziv, G. Zirpoli, A. M. Thompson, V. C. Jordan, Y. Nakamura, R. B. Altman, M. M. Ames, R. M. Weinshilboum, M. Eichelbaum, J. N. Ingle, T. E. Klein (Lead / Corresponding author)

    Research output: Contribution to journal › Article › peer-review

    346 Downloads (Pure)

    Abstract

    The International Tamoxifen Pharmacogenomics Consortium was established to address the controversy regarding cytochrome P450 2D6 (CYP2D6) status and clinical outcomes in tamoxifen therapy. We performed a meta-analysis on data from 4,973 tamoxifen-treated patients (12 globally distributed sites). Using strict eligibility requirements (postmenopausal women with estrogen receptor-positive breast cancer, receiving 20?mg/day tamoxifen for 5 years, criterion 1); CYP2D6 poor metabolizer status was associated with poorer invasive disease-free survival (IDFS: hazard ratio = 1.25; 95% confidence interval = 1.06, 1.47; P = 0.009). However, CYP2D6 status was not statistically significant when tamoxifen duration, menopausal status, and annual follow-up were not specified (criterion 2, n = 2,443; P = 0.25) or when no exclusions were applied (criterion 3, n = 4,935; P = 0.38). Although CYP2D6 is a strong predictor of IDFS using strict inclusion criteria, because the results are not robust to inclusion criteria (these were not defined a priori), prospective studies are necessary to fully establish the value of CYP2D6 genotyping in tamoxifen therapy.
    Original languageEnglish
    Pages (from-to)216-227
    Number of pages12
    JournalClinical Pharmacology & Therapeutics
    Volume95
    Issue number2
    Early online date23 Sept 2013
    DOIs
    Publication statusPublished - Feb 2014

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Fingerprint

    Dive into the research topics of 'CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations'. Together they form a unique fingerprint.

    Cite this